Bio-M BioM is a service and consulting company whose aim is to promote the development of the Munich Biotech Cluster as an internationally renowned centre of excellence in the field of innovative biotechnology. It is the first point of contact for biotech start-up companies seeking financial support or business advice. Through the BioM network which includes all important players in the region (representatives from public offices, scientific institutions, venture capitalists and biotech companies), BioM assists Munich-based companies in finding the right contacts and partners. |
 |
Citigate Dewe Rogerson Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia. Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors. The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia. Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million). |
 |
College Hill College Hill Life Sciences provides a full service communications consultancy focused on science-based sectors. Within the life science field we have established a leadership position by working in partnership with our clients to deliver high quality communications that build corporate value and promote leading edge products, technologies and services). |
 |
Going Public Media AG Founded in1998 GoingPublic Media AG is today one of the leading publishers of magazines on technology trends, corporate finance and capital markets. 70-80 magazines, newsletters and books are being edited, printed and distributed each year. In addition to the monthly issued “GoingPublic Magazin” and its well known yearly special editions like “Corporate Finance & Private Equity Guide” or “Biotechnology” which are largely meant as reference books, the company publishes the likewise monthly “VentureCapital Magazin” (www.venturecapital.de). It stands as a hub for the private equity and venture capital industry in German speaking Europe and addresses investors and entrepreneurs who focus on trends in technology, corporate financing and venture capital/private equity. Special topics are additionally treated in supplements and special editions (“Tech-Guide”, “Start-up” a.o.). Since 2003, GoingPublic Media AG addresses retail investors via its subsidiary Smart Investor Media GmbH and the monthly issued magazine Smart Investor. The quarterly published “HV Magazin” focuses on organizational, technical and legal trends concerning the annual shareholder meeting and is directed to the responsibles of listed companies (CFOs, investor relations managers etc.). New in 2007 is “Unternehmeredition”, which focuses quarterly on Small and Medium-sized Business Entrepreneurs. Furthermore GoingPublic Media operates the corporate publishing division GoingPublic Services. About 10 magazines and newsletters are annually distributed on behalf of well-known venture capital companies and financial institutions. Since November 2006 GoingPublic Media is listed in the open market of Frankfurt stock exchange. The complete prospectus can be found at www.goingpublic.de/ir. All publications are published in German. Contact: Markus Rieger, CEO Websites: www.goingpublic.de, www.vc-magazin.de, www.hv-magazin.de, www.smartinvestor.de, www.unternehmeredition.de |
 |
PharmaDeals Whether you require data for benchmarking, competition analysis or simply to find out what new intellectual properties are being licensed, PharmaDeals® gives you access to the latest deal making information in the pharmaceutical and biotech field. Intelligently indexed, the new PharmaDeals v2 database is the ultimate benchmarking tool. PharmaDeals is brought to you by PharmaVentures, Experts in Deals and Alliances. With PharmaDeals v2, you benefit from using this unique set of business tools that offers you a flexible and cost effective resource to assist you in your deal making activities:
Find out more about PharmaDeals: www.pharmadeals.net If you would like to request a demonstration of PharmaDeals v2, please contact Silvia Serra on +44 (0) 1865 784 195 or e-mail sales@pharmaventures.com. PharmaDeals® is a registered Trade Mark of PharmaVentures Ltd. |
 |
Tiberend Strategic Advisors, Inc. Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies. 1. To enhance valuation |
 |